Previous close | 1.2440 |
Open | 1.2500 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.2500 - 1.2500 |
52-week range | 1.0400 - 2.3200 |
Volume | |
Avg. volume | 850 |
Market cap | 27.561M |
Beta (5Y monthly) | -0.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, July 03, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
TOULOUSE, France & LAKELAND, Mich., July 01, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the success of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number
TOULOUSE, France & LAKELAND, Mich., June 27, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were unanimously approved.